![]() |
Name |
Furaquinocin I
|
Molecular Formula | C22H24O8 | |
IUPAC Name* |
(E,5R)-5-hydroxy-5-[(2R,3S)-4-hydroxy-7-methoxy-2,3,8-trimethyl-6,9-dioxo-2H-benzo[g][1]benzofuran-3-yl]-2-methylpent-2-enoic acid
|
|
SMILES |
C[C@@H]1[C@](C2=C(C=C3C(=C2O1)C(=O)C(=C(C3=O)OC)C)O)(C)[C@@H](C/C=C(\C)/C(=O)O)O
|
|
InChI |
InChI=1S/C22H24O8/c1-9(21(27)28)6-7-14(24)22(4)11(3)30-20-15-12(8-13(23)16(20)22)18(26)19(29-5)10(2)17(15)25/h6,8,11,14,23-24H,7H2,1-5H3,(H,27,28)/b9-6+/t11-,14-,22-/m1/s1
|
|
InChIKey |
JJZAZDAEVNRFGT-PILGHQHZSA-N
|
|
Synonyms |
Furaquinocin I; DTXSID601043758; Q44212329; 1344118-45-1
|
|
CAS | 1344118-45-1 | |
PubChem CID | 53387829 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 416.4 | ALogp: | 2.5 |
HBD: | 3 | HBA: | 8 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 130.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 30 | QED Weighted: | 0.624 |
Caco-2 Permeability: | -5.118 | MDCK Permeability: | 0.00001140 |
Pgp-inhibitor: | 0.09 | Pgp-substrate: | 0.03 |
Human Intestinal Absorption (HIA): | 0.021 | 20% Bioavailability (F20%): | 0.008 |
30% Bioavailability (F30%): | 0.021 |
Blood-Brain-Barrier Penetration (BBB): | 0.149 | Plasma Protein Binding (PPB): | 86.26% |
Volume Distribution (VD): | 0.797 | Fu: | 8.09% |
CYP1A2-inhibitor: | 0.342 | CYP1A2-substrate: | 0.819 |
CYP2C19-inhibitor: | 0.101 | CYP2C19-substrate: | 0.076 |
CYP2C9-inhibitor: | 0.439 | CYP2C9-substrate: | 0.505 |
CYP2D6-inhibitor: | 0.629 | CYP2D6-substrate: | 0.094 |
CYP3A4-inhibitor: | 0.191 | CYP3A4-substrate: | 0.179 |
Clearance (CL): | 1.979 | Half-life (T1/2): | 0.652 |
hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.05 |
Drug-inuced Liver Injury (DILI): | 0.955 | AMES Toxicity: | 0.054 |
Rat Oral Acute Toxicity: | 0.169 | Maximum Recommended Daily Dose: | 0.337 |
Skin Sensitization: | 0.211 | Carcinogencity: | 0.052 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.023 |
Respiratory Toxicity: | 0.198 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002104 | ![]() |
0.821 | D0B9EJ | ![]() |
0.256 | ||
ENC002147 | ![]() |
0.814 | D0WY9N | ![]() |
0.256 | ||
ENC005159 | ![]() |
0.375 | D01XWG | ![]() |
0.247 | ||
ENC005551 | ![]() |
0.367 | D0N1FS | ![]() |
0.246 | ||
ENC005156 | ![]() |
0.361 | D0Q0PR | ![]() |
0.245 | ||
ENC006089 | ![]() |
0.354 | D0T5XN | ![]() |
0.234 | ||
ENC003047 | ![]() |
0.346 | D07VLY | ![]() |
0.233 | ||
ENC003141 | ![]() |
0.343 | D0C9XJ | ![]() |
0.233 | ||
ENC003531 | ![]() |
0.330 | D0C1SF | ![]() |
0.231 | ||
ENC005197 | ![]() |
0.318 | D01XDL | ![]() |
0.229 |